CRISPR-Based Approaches for Cancer Immunotherapy DOI
Rama Rao Malla,

Keerthana Middela

Critical Reviews™ in Oncogenesis, Journal Year: 2023, Volume and Issue: 28(4), P. 1 - 14

Published: Jan. 1, 2023

Clustered regularly interspaced short palindromic repeats (CRISPR) technology is a powerful gene editing tool that has the potential to revolutionize cancer treatment. It allows for precise and efficient of specific genes drive growth progression. CRISPR-based approaches knock-out, which deletes or sequences DNA within cell, knock-in, inserts new into cell identify targets therapy. Further, genome-wide CRISPR-Cas9-based screens markers diagnosis cancers. Recently, immunotherapy become highly strategy treatment cancer. The use CRISPR in focused on enhancing function T cells, making them more effective at attacking cells inactivating immune evasion mechanisms cells. generate CAR-T are have been genetically engineered target attack specifically. This review uncovers latest developments strategies delivery their components In addition, applications therapy discussed. Overall, this helps explore clinical settings.

Language: Английский

Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy DOI Creative Commons
Jie Wang, Zilong Zhang, Yan Zhuo

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(8), P. 3643 - 3660

Published: April 15, 2024

The prospect of employing chemoimmunotherapy targeted towards the endoplasmic reticulum (ER) presents an opportunity to amplify synergistic effects chemotherapy and immunotherapy. In this study, we initially validated celastrol (CEL) as inducer immunogenic cell death (ICD) by promoting ER stress autophagy in colorectal cancer (CRC) cells. Subsequently, ER-targeted strategy was posited, involving codelivery CEL with PD-L1 small interfering RNAs (siRNA) using KDEL peptide-modified exosomes derived from milk (KME), enhance outcomes. Our findings demonstrate efficient transportation KME via Golgi-to-ER pathway. Compared their non-targeting counterparts, exhibited a significant augmentation CEL-induced ICD effect. Additionally, it facilitated release danger signaling molecules (DAMPs), thereby stimulating antigen-presenting function dendritic cells infiltration T into tumor. Concurrently, delivery siRNA resulted downregulation both intracellular membrane protein expression, consequently fostering proliferation activity CD8+ Ultimately, formulation enhanced anti-tumor efficacy provoked immune responses against orthotopic tumors vivo. Collectively, robust provides encouraging approach for achieving potent chemoimmunotherapy.

Language: Английский

Citations

11
Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis DOI Creative Commons
Jie Tan,

Qianfei Xue,

Xiao Hu

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 23, 2024

Abstract Idiopathic pulmonary fibrosis (IPF) is a globally prevalent, progressive disease with limited treatment options and poor prognosis. Because of its irreversible progression, IPF affects the quality length life patients imposes significant burden on their families social healthcare services. The use antifibrotic drugs pirfenidone nintedanib can slow progression to some extent, but it does not have reverse effect option lung transplantion also owing contraindications transplantation, possible complications after risk death. Therefore, discovery new, effective methods an urgent need. Over recent years, various studies been undertaken investigate relationship between interstitial pneumonia cancer, suggesting that immune checkpoints in are similar those tumors. Immune class immunosuppressive molecules essential for maintaining autoimmune tolerance regulating duration magnitude responses peripheral tissues. They prevent normal tissues from being damaged destroyed by response. While current focused PD-1/PD-L1 CTLA-4, may be only checkpoint treatment. This review discusses application IPF, aim finding new direction

Language: Английский

Citations

7
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy DOI Creative Commons

Deepa Rajagopal,

Elliot MacLeod,

Diana Corogeanu

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(13)

Published: July 1, 2024

Abstract Recombinant antibodies (Abs) are an integral modality for the treatment of multiple tumour malignancies. Since Food and Drug Administration (FDA) approval rituximab as first monoclonal antibody (mAb) cancer treatment, several mAbs (Ab)‐based therapies have been approved solid malignancies other cancers. These Abs function by either blocking oncogenic pathways or angiogenesis, modulating immune response, delivering a conjugated drug. The use Ab‐based therapy in patients who could benefit from however, is still limited associated toxicity profiles which may stem biological features processes related to target binding, alongside biochemical and/or biophysical characteristics therapeutic Ab. A significant immune‐related adverse event (irAE) with cytokine release syndrome (CRS), characterized development fever, rash even marked, life‐threatening hypotension, acute inflammation secondary systemic uncontrolled increase range pro‐inflammatory cytokines. Here, we review irAEs specific classes approved, novel immunotherapeutics, namely checkpoint (IC)‐targeting Abs, bispecific (BsAbs) Ab‐drug‐conjugates (ADCs), highlighting significance harmonization preclinical assay safety assessment biotherapeutics approach support refine clinical translation.

Language: Английский

Citations

4
Breast cancer stroma and its components: Implication in diagnostic and therapeutic DOI
Riya Sharma, Pankaj Kumar, Vijay Kumar

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 43 - 68

Published: Jan. 1, 2025

Language: Английский

Citations

0
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond DOI
Durre Aden, Samreen Zaheer, Niti Sureka

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155864 - 155864

Published: March 1, 2025

Language: Английский

Citations

0
Hypoxia and programmed cell death-ligand 1 expression in the tumor microenvironment: a review of the effects of hypoxia-induced factor-1 on immunotherapy DOI
Fateme Khani Chamani,

Atefe Etebari,

Mahsa Hajivalili

et al.

Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)

Published: Jan. 6, 2024

Language: Английский

Citations

3
Advances in cancer therapy: unveil the immunomodulatory protein involved in signaling pathways as molecular targets DOI
Chandrabose Selvaraj,

Santhosh Rajendran,

Abdulaziz S. Alothaim

et al.

Chemical Papers, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Language: Английский

Citations

0
Recent advances in PD-L1 siRNA nanocarriers for cancer therapy DOI

Sristi,

Garima Gupta, Mohammed A. S. Abourehab

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 143994 - 143994

Published: May 1, 2025

Language: Английский

Citations

0
Exploring the Tumor Microenvironment of Anaplastic Thyroid Carcinoma and its impact on Patient Survival DOI
Chanchal Rana, Prabhakar Mishra,

Kulranjan Singh

et al.

Published: May 9, 2025

Abstract Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by nearly 100% mortality and significant therapeutic challenges. This study investigated the tumour microenvironment (TME) in ATC, focusing on immune checkpoint molecules (PD-L1/PD-1), tumour-associated macrophages (TAMs), E-cadherin expression. A retrospective cohort of 22 ATC patients treated at King George’s Medical University, Lucknow, India, between January 2017 August 2022, was analyzed. Immunohistochemical evaluation revealed PD-L1 expression 68.2% cases, with median proportion score (TPS) 50. PD-1 limited to inflammatory cells. loss observed over 69% suggesting disrupted cell adhesion. TAM infiltration elevated 58.8% correlated significantly (p = 0.02). Survival analysis demonstrated mean overall survival 3 months, high expression, density, increased associated shorter < 0.001). Patients expressing had 2.4 months compared 4.1 for those without 0.05). Similarly, cells poorer outcomes (mean 2.5 versus 4.5 low expression; p 0.03). These findings underscore critical role markers within TME influencing prognosis. The associations PD-L1, highlight potential targeted immunotherapeutic strategies improve ATC. Further research warranted clarify predictive value these guiding treatment approaches.

Language: Английский

Citations

0
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe? DOI Creative Commons
Aimin Jiang, Na Liu, Jingjing Wang

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Dec. 5, 2022

Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with bleak prognosis. Mounting evidence suggests that IPF shares bio-molecular similarities cancer. Given the deep understanding of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in cancer immunity and successful application immune checkpoint inhibitors (ICIs) cancer, recent studies have noticed role PD-1/PD-L1 axis IPF. However, conclusions are ambiguous, latent mechanisms remain unclear. In this review, we will summarize based on current murine models clinical studies. We found plays more predominant profibrotic than its immunomodulatory by interacting multiple types pathways. Most preclinical also indicated blockade could attenuate severity mice models. This review bring significant insights into identifying new therapeutic targets.

Language: Английский

Citations

16